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We  investigated  the  role  of  carbohydrate  antigen  sialyl-Lewis  a (sLea),  an E-selectin  ligand  and  epitope
of tumor  marker  CA19.9,  in the  development  of  xenografts  in nude  mice.  To this  end, animals  were
inoculated  with  the  human  colon  cancer  cell  line  HCT-15,  expressing  no  Lewis  antigens,  or with  a  clone
expressing  sLea  (HCT-15-T5).  The  size  of  HCT-15-T5  xenografts  appeared  larger  than  those  of HCT-15  and
their average  weight  was  over  twice  bigger.  In both xenografts  the  mitotic  index  was found  elevated,  as
determined  by  Ki-67  assay,  and  no  apoptosis  was  detected  in  the  tumor  cells by both  caspase  8 or  TUNEL
assays.  Some  apoptotic  signals  were  instead  detected  in  the  vessels.  Conversely,  microvessel  density,
determined  through  CD-31  immunohistochemistry,  was  found  3.2-folds  bigger  in  HCT-15-T5  xenografts
(p  <  0.012).  Only  the  membranes  of  HCT-15-T5  cells  grown  as  xenografts  reacted  intensively  with  the  anti
CA19.9  antibody  1116-NS-19-9  by immunoﬂuorescence,  but not  by immunohistochemistry.  Unknown
structures  were  instead  stained  by  such  technique  in both  xenografts,  as were  in  mouse  tissues  not
expressing  the antigen  and  in human  colon  adenocarcinoma.  We  conclude  that  expression  of  sLea  on the
surface  of  colon  cancer  cells improves  xenograft  growth  and is associated  with  enhanced  angiogenesis,
while  immunohistochemistry  with  1116-NS-19-9  antibody  appears  not  suitable  to  determine  CA19.9
expression.
© 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Lewis antigens are a group of oligosaccharide residues con-
stituting the end of various carbohydrate chains of glycoproteins
and glycolipids protruding from the outer surface of mammalian
cell membranes (Marionneau et al., 2001). Among them, sialy-
lated Lewis antigens sLex and sLea were found to act as speciﬁc
E-selectin ligands, and are thus potentially involved in many cell
adhesion events (Läubli and Borsig, 2010). At present, sLex is a well-
established E- and P-selectin ligand involved in leukocyte homing
and neutrophil rolling to the vascular endothelium at the sites of
inﬂammation (Sperandio, 2006). It was also found associated to
malignancy when expressed on the surface of epithelial tumors,
Abbreviations: sLea, sialyl-Lewis a, NeuAc2-3Gal1-3[Fuc1-4]GlcNAc; sLex,
sialyl-Lewis x, NeuAc2-3Gal1-4[Fuc1-3]GlcNAc; H&E, hematoxylin–eosin;
TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.
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and considered potentially involved in metastasis formation (St
Hill, 2011).
sLea is an isomer of sLex, where the backbone disaccharide
Gal1,4GlcNAc (type 2 chain) is replaced by Gal1,3GlcNAc (type
1 chain). The shift to type 1 chain synthesis is due to the expression
of 1,3galactosyltransferase 3Gal-T5 (Isshiki et al., 1999). Due to
the cell and tissue speciﬁc expression of 3Gal-T5 versus the almost
ubiquitous expression of 1,4galactosyltransferases, type 1 chains
are restricted to selected cell types. The biological role of sLea is
unclear: it is present in the blood of many healthy individuals as the
epitope of CA19.9 antigen, that is found elevated in various diseases,
including cancers. At present it is recommended as a serum marker
for the management of pancreatic cancer (Duffy et al., 2010). It was
also proposed as an alternative to sLex in promoting cancer malig-
nancy (Kannagi et al., 2004), although few experimental data are
available so far. Moreover, the actual ability of colon cancer cells to
synthesize sLea is controversial (Mare et al., 2013), since 3Gal-T5
is down-regulated in some cancers (Salvini et al., 2001; Isshiki et al.,
2003; Caretti et al., 2012).
To address the function of sLea, we  previously transfected the
human colon cancer cell line HCT-15, which lacks expression of
any Lewis antigen, with 3Gal-T5 cDNA and generate recombinant
1357-2725/$ – see front matter ©  2013 Elsevier Ltd. All rights reserved.
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clones expressing type 1 chain Lewis antigens, mostly sLea, and
no sLex (Mare and Trinchera, 2004). To assess whether or not sLea
expression is maintained by tumor cells growing in vivo and affects
tumor growth, a well characterized clone, named HCT-15-T5,
together with the parental HCT-15 cells, was subcutaneously inoc-
ulated in nude mice, and the development of xenografts studied. In
particular, we compared the growth and size of the xenografts, and
characterized the main biochemical and morphological features.
2. Materials and methods
2.1. Cells and transfected cell clone
COLO-205 and SW-1116 cell lines were cultured as reported
(Mare et al., 2013), rat cardiomyocytes H9c2 (ATCC CRL 1446) and
mouse photoreceptor derived 661 W cells (a gift by Dr. R. Ghi-
doni, University of Milan) were cultured in DMEM containing 10%
fetal bovine serum, 100 U/ml penicillin, 1 mg/ml  streptomycin, and
2 mM l-glutamine. HCT-15-T5 clone was obtained by transfection
of human colon cancer cell line HCT-15 (ATCC CCL-225) with the
coding sequence of 3Gal-T5 cDNA inserted in pCDM8 vector, as
reported (Mare and Trinchera, 2004).
For microscopy studies, cells were harvested with 3 mM EDTA
in PBS, washed in PBS, and centrifuged at room temperature for
5 min  at 12,000 × g. Pellets were soaked with 0.5 ml  of buffered
10% formalin solution, ﬁltrated in ﬁlter bags, embedded in parafﬁn,
and then processed for immunohistochemistry and immunoﬂuo-
rescence as for tissue sections.
2.2. Xenografts
Seven-week-old Foxn1nu/nu mice (Harlan), weighing 25–30 g
at the entry into the study, were cared as reported (Terraneo
et al., 2010). Cells were resuspended in PBS at a ﬁnal concentra-
tion of 2 × 106/0.1 ml  and 0.1 ml  inoculated in each ﬂank using
a 26G insulin syringe starting from the same cell suspension for
all the experiments. Xenograft growth was monitored as reported
(Terraneo et al., 2010). After euthanasia by cervical dislocation,
xenografts were quickly dissected away from surrounding skin and
weighed. They were immediately cut in two parts: one frozen in
liquid nitrogen and stored at −80 ◦C for biochemical analyses, and
another ﬁxed in formalin and embedded in parafﬁn for H&E stain-
ing, immunohistochemistry, or immunoﬂuorescence.
2.3. DNA analysis
Genomic DNA was extracted from xenograft specimens rid of
capsular material, or from mouse liver or human HCT-15 cells, using
a commercially available kit (QIAamp DNA, Qiagen) and submitted
to competitive PCR as reported (Mare and Trinchera, 2007). Ampli-
ﬁcation program (30 cycles) included a single treatment at 94 ◦C
for 3 min  followed by cycles consisting of 1 min  at 94 ◦C (melting),
1.5 min  at 66 ◦C (annealing), 1.5 min  at 72 ◦C (extension), and a ﬁnal
extension step at 72 ◦C for 8 min.
2.4. Immunohistochemistry
Immunohistochemical studies were carried out on 4 m thick
tissue sections using a Novolink Polymer Detection System
(Novocastra Laboratories) with the following primary antibod-
ies. Ki-67 mouse monoclonal MIB1 (Dako), 1:100 dilution; CD-31
mouse monoclonal JC70A (Dako), 1:50 dilution; Caspase 8 rabbit
monoclonal E6 (Abcam), 1:100 dilution; sLea mouse monoclonal
1116-NS-19-9 (ATCC HB-8059), 1:3000 dilution, prepared and
puriﬁed as reported (Bardoni et al., 1999).
Sections were deparafﬁnized in BioClear (Bio Optica) for 20 min,
washed twice in ethanol, and kept 30 min at 95 ◦C in 9 mM sodium
citrate pH 6.0. Endogenous peroxidase activity was quenched with
3% H2O2 for 10 min. Staining was performed with 3,3diaminoben-
zidine as a chromogen. Slides were immunostained in the same
batch, including negative controls lacking the primary antibody.
To quantify Ki-67 or caspase 8 immunostaining, the ratio
between positive and total nuclei was  calculated in ﬁve random
microscopic areas at 60× by two independent observers with 100%
agreement in the calculation of ratio. To quantify the number of
intra-tumoral vessels, the number of CD-31 positive areas was cal-
culated as for Ki-67 but at 40×.  Necrotic areas were avoided during
the calculation.
2.5. Immunoﬂuorescence
Parafﬁn-embedded sections were deparafﬁnized with the fol-
lowing sequential treatments. Xylene, 3 times (5 min each); 100%
ethanol, twice (5 min  each); 95% and 70% ethanol (3 min each); dis-
tilled water (30 s), and PBS (5 min). Sections were post-ﬁxed with
ethanol:acetic acid, 2:1 (vol:vol) at −20 ◦C for 5 min, rinsed twice
in PBS for 5 min, boiled in 10 mM citrate buffer, pH 6.0, for 10 min,
cooled at room temperature for 20 min, and washed twice in PBS.
Apoptosis was assessed using the TUNEL assay as already
reported (Caretti et al., 2013). Total nuclei were counterstained
with the karyophilic dye Hoechst 33258 (300 ng/ml, Sigma) for
3 min  at room temperature, in the dark, followed by rinsing twice
in PBS and cover slipping. Immunostaining with anti sLea (1:500)
was performed according to the procedure of Terraneo et al. (2010).
2.6. Statistical analysis
To detect differences among the groups, we performed unpaired
t test with Welch correction.
3. Results
3.1. Development of HCT-15 and HCT-15-T5 xenografts in nude
mice
The clone selected for the experiments (HCT-15-T5) was found
to express 3Gal-T5 activity and mRNA, as well as type 1 chain
Lewis antigens, including sLea, as previously reported in details
(Mare and Trinchera, 2004). sLea levels were similar to those of
SW-1116 cells, a typical cell model for sLea studies. In a ﬁrst exper-
iment, nude mice receiving subcutaneous injection of HCT-15 and
HCT-15-T5 were found to develop visible nodules at the sites of
injection with high frequency. The size of HCT-15-T5 xenografts
appeared larger than those of HCT-15. The difference was  recog-
nized after 2-3 weeks and became more evident in the following
days (Fig. 1A, left panel). After 23 days, few xenografts appeared
so big to start sacriﬁcing the animals and collecting the masses. In
other cases, they were allowed to growth for additional weeks. Such
differences in growth rate are probably due to the intrinsic exper-
imental variability. In the end, out of 8 animals injected on both
sides with either cells, 14 xenografts were detected upon injec-
tion of both HCT-15 and HCT-15-T5 cells. The average weight of
xenografts (Fig. 1A, right panel) was  found to be 2.4-fold bigger
in the case of HCT-15-T5, and such difference appears signiﬁcant
(p < 0.031). In a second experiment performed under identical con-
ditions, all animals were sacriﬁced 30 days after the injection, and
we obtained similar results (Fig. 1B). In fact, 16 and 15 xenografts
were detected upon injection of HCT-15 and HCT-15-T5, respec-
tively, and the size of those obtained with HCT-15-T5 was  bigger:
the average weight was twice larger than that with HCT-15 cells
(p < 0.039). The collected tumor masses appeared rather pales in
Author's personal copy
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Fig. 1. Development of HCT-15 and HCT-15-T5 xenografts in nude mice. The growth
of  xenografts was  determined three times a week as reported (Terraneo et al., 2010).
(A) 3 out of 8 mice of each group (dotted lines) were sacriﬁced after 23 days and the
xenografts removed, while the others were allowed to growth 2 additional weeks
(full lines). Twelve xenografts were collected and weighted from each group. (B) All
16  animals were sacriﬁced after 30 days, and 9 or 14 xenografts were collected
and  weighted after HCT-15 or HCT-15-T5 injection, respectively. After euthana-
sia, xenografts were dissected away and weighed. The difference in the average
xenograft weigh obtained from the 2 groups was found signiﬁcant (p < 0.031 and
p  < 0.039 in experiments A and B, respectively).
both cases, and some xenografts contained amorphous ﬂuid mate-
rial released upon manipulation or cutting.
3.2. Characterization of HCT-15 and HCT-15-T5 xenografts
To understand the mechanisms underlying the differences in
xenograft size, xenografts collected at 30 days post injection were
analyzed by various techniques. Histologically, xenografts from
both groups appear largely necrotic (Fig. 2A). In addition to cancer
cells, an abundant stromal tree was evident, with some vessel-
like structures inside. DNA analysis showed that xenografts contain
cells originated from the mouse host, as much as from the injected
human cells. In fact, the amount of mouse and human genomic
DNA detected in various xenograft specimens was similar, as deter-
mined by competitive PCR (supplemental Fig. S1), suggesting that
only the epithelial cells derive from the injected human cancer
cells, while the whole stroma was built around by the mouse host.
The mitotic index was found elevated, as determined by Ki-67
assay, without differences between HCT-15 and HCT-15-T5 cells
(Fig. 2B). No apoptosis was detected in both cases, by caspase 8
(Fig. 2C) or TUNEL (Fig. 2D) assays, in the tumor cells. However,
some apoptotic signals were evident by both procedures in the ves-
sels (see insets). These data suggest that the difference in size was
not due to intrinsic differences in cell growth or cell survival, but
instead to the interaction between the cells and the host tissue. We
thus evaluated the presence and density of microvessels, deter-
mining the amount of CD-31 as a marker of vascular endothelium.
Immunohistochemistry (Fig. 2E) showed that in the case of HCT-15
xenografts intratumoral CD-31 is rather poor, while in the case of
HCT-15-T5 xenografts, that express sLea, it was 3.2-folds more evi-
dent (p < 0.012). Noteworthy, some vessel-like structures negative
to CD-31 were recognized in both xenografts.
Supplementary material related to this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.biocel.2013.10.003.
Fig. 2. Immunohistochemical characterization of xenografts. Xenografts developed
in  nude mice after inoculation of HCT-15 or HCT-15-T5 cells were processed as
reported under Section 2. Results shown in the bar graphs are the mean ± standard
deviation for ﬁve random microscopic areas examined at the indicated magniﬁca-
tion by two independent observers. Representative ﬁelds are presented. Scale bars
are 100 m in the main ﬁelds (except H&E) or 50 m in the insets. (A) H&E stain-
ing of xenograft sections examined by light microscopy (magniﬁcation 2×) showing
conserved parenchyma (strong staining) and necrotic areas (pale zones). Percent of
necrosis was calculated semi quantitatively by the ratio between pale and strong
staining areas. (B) Ki-67 immunohistochemistry (magniﬁcation 60×)  showing abun-
dant reactivity in both cases. (C) Caspase 8 immunohistochemistry (magniﬁcation
20×)  showing almost no apoptotic tumor cells in both xenografts. Inset: reactiv-
ity detected in some vessels (magniﬁcation 60×). (D) TUNEL assay of xenograft
sections examined by ﬂuorescence microscopy. Fragmented DNA ends were red-
labeled by TMR  while total nuclei were blue-counterstained with Hoechst 33258.
Merged images are presented, where pink (apoptotic) nuclei are detected in putative
endothelial cells of some vessels, but not in tumor cells of both xenografts (magniﬁ-
cation 40×). (E) CD-31 immunohistochemistry (magniﬁcation 60×) showing more
abundant reactivity in HCT-15-T5 xenografts. The number of reactive intra-tumoral
vessels was calculated per microscopic ﬁeld at 40× avoiding necrotic areas. The
difference between xenografts was found signiﬁcant (p < 0.012).
3.3. Detection of sLea in the xenografts
To conﬁrm that parental HCT-15 cells do not express sLea when
growing as a xenograft, while HCT-15-T5 do express the antigen,
immunoﬂuorescence with anti sLea was  performed on the above
sections using CA19.9 antibody (1116-NS-19-9). No ﬂuorescence
at all was detected in HCT-15 xenografts, while a bright positivity
was found in HCT-15-T5 xenografts (Fig. 3, left side). Labeling was
Author's personal copy
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Fig. 3. Detection of sLea by immunoﬂuorescence or immunohistochemistry. Sec-
tions were prepared and processed as reported under Section 2, following the
procedure reported by Portela et al. (2011) for immunohistochemistry with 1116-
NS-19-9 antibody. Magniﬁcation is 40× for immunoﬂuorescence, 40× (xenografts
and high grade colon dysplasia) or 60× (mouse tissues and poorly differentiated
area of colon adenocarcinoma) for immunohistochemistry. Scale bars = 100 m
(immunohistochemistry of xenografts and high grade colon dysplasia) or 50 m
(all  others). Immunoﬂuorescence detection of CA19.9 antigen is evident on the
cell membranes of HCT-15-T5 xenograft only, which are not labeled by immuno-
histochemistry. Nuclei were blue-counterstained with Hoechst 33258 as reference
(insets). Other unknown structures, not membrane-bound, are instead stained by
immunohistochemistry in all sections. Note that immunohistochemistry results
obtained with human colon cancer are very similar to those recently published
(Portela et al., 2011).
typically located on the cell membrane, resembling the feature of
HCT-15 cells growing in culture, and not in the stromal tree of
mouse origin. Surprisingly, using the same antibody by immuno-
histochemistry, we found poor and opposite labeling of HCT-15-T5
xenografts (Fig. 3, right side). In fact, tumor cells were totally not
reactive, while some reactivity was detected in the stroma, and
not at the level of cell membranes. Even more surprisingly, the
same pattern was also found in HCT-15 xenografts. We  also stained
tissue sections from different organs of the same mice as well as
Fig. 4. Immunohistochemistry with anti sLea antibody 1116-NS-19-19 in refer-
ence cell lines. Cultured cell lines were harvested with 3 mM EDTA, washed in
PBS, ﬁltrated in ﬁlter bags, embedded in parafﬁn, and then processed for immuno-
histochemistry and immunoﬂuorescence as for tissue sections in Fig. 3. Scale
bars = 100 m.  Insets: merged images are presented for immunoﬂuorescence, where
blue  nuclei are detected in all cells and enclosed into green plasma membranes
in  positive cells only. No reactive cells were detected by immunohistochemistry.
For comparison, other tissues reactive under the reported conditions are shown on
the  right side. Scale bars = 400 m (magniﬁcation 10×), or 100 m (magniﬁcation
40×).  Note the reactivity of adipocytes and vessels in the mouse adipose tissue, the
lack  of reactivity of enterocytes in the mouse small intestine, where instead some
blood-borne cells (presumably macrophages) are strongly reactive, and the diffuse
reactivity of pneumocytes in the mouse lung versus the restricted reactivity of the
bronchiolar surface in the human lung.
from an independent C57BL/6 mouse. We  did ﬁnd reactivity in var-
ious sections of all mice, including the colon and the liver (Fig. 3)
Interestingly, we  found a similar pattern by CA.19.9 immunohisto-
chemistry of a human colon adenocarcinoma (Fig. 3), that instead
was almost negative by immunoﬂuorescence, as were all the mouse
sections.
To conﬁrm the result (Fig. 4), we  stained two reference cell lines
as positive controls, COLO-205 and SW-1116. The former expresses
the highest levels of sLea reported (Mare and Trinchera, 2004), and
the latter is the one originally used as immunogen for develop-
ing 1116-NS-19-9 hybrydoma (Koprowski et al., 1979). Rodent cell
lines were stained as the negative controls. Utilizing the identical
procedure used for the above tissue sections, even COLO-205 and
SW-1116 were totally negative by innunohistochemistry, while
other tissues, as the lung, the small intestine, and the adipose tis-
sue, were clearly reactive. This indicates that the antibody detects
no sLea at all by immunohistochemistry, but instead unknown
molecules commonly expressed in mouse and human tissues.
4. Discussion
In this paper we found that the expression of sLea on the sur-
face of colon cancer cells HCT-15 improves xenograft growth and
is associated with enhanced angiogenesis.
HCT-15 cells appeared highly tumorigenic in nude mice; in
fact, we obtained successful xenografts after almost all injections.
Such cells replicated very fast and escaped apoptosis, as assessed
by Ki-67, caspase 8, and TUNEL assays, but failed to give raise
to very large tumors and quickly became necrotic. We hypoth-
esize that HCT-15 cells grow faster than the rate they stimulate
vascularization, probably because they lack to express multiple
angiogenic stimuli. In fact, few CD-31 reactive microvessels were
recognizable inside the xenograft structure. On the other side the
presence of the E-selectin ligand sLea on the surface of HCT-15-T5
xenografts was associated with a recognizable network of CD-31
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positive microvessels that appeared able, at least in part, to sus-
tain cell growth. This suggests that sLea is able to restore the
angiogenic stimulus, at least in part, probably acting as a ligand
for E-selectin expressed by endothelial cells. We  also found that
xenografts derived from both HCT-15 and HCT-15-T5 cells showed
an abundant stromal architecture derived from the host where
some endothelial-like cells were present, but appeared CD-31
negative. Since we found that some of them were apoptotic, we
speculate that such CD-31 negative endothelial-like cells may  be
not living, and not able to give rise to functional vessels. Conversely,
in the presence of sLea, at least a part of the recruited endothe-
lial cells may  remain alive and maintain functional vessels. This
would be in agreement with the role already assigned to other
adhesion molecules in speciﬁc steps of angiogenesis (Ramjaun
and Hodivala-Dilke, 2009) and with that speciﬁcally suggested for
E-selectin in melanoma growth (Liu et al., 2011). Interestingly, in
another model of xenograft growth, the selectin ligand isomer sLex
provided similar angiogenic effects (Mathieu et al., 2007). Previ-
ously, an angiogenic role of sLex and sLea together was  reported in
a study that involved the cotransplantation of cancer and endothe-
lial cells (Tei et al., 2002). To our knowledge, data here presented are
the ﬁrst demonstrating the actual ability of sLea alone to promote
tumor angiogenesis in a nude mice model.
Another relevant ﬁnding of the present study is the evi-
dence that the anti-sLea antibody 1116-NS-19-9 is not suitable
for immunohistochemistry. In fact, we found that HCT-15-T5
xenografts, where the membranes of epithelial cells were well
reactive with the antibody by immunoﬂuorescence, were not by
immunohistochemistry. Even COLO-205 and SW-1116 cells, which
are the prototype of cells expressing sLea, were not stained by
immunohistochemistry. Moreover, various unknown structures
that were negative by immunoﬂuorescence did react by immuno-
histochemistry even in HCT-15 xenografts, as well as in various
mouse tissues. Since sLea is not synthesized in the rodents (Falk
et al., 1995), due to the lack of any 1,4 fucosyltransferase activ-
ity (Dupuy et al., 2002), it is evident that 1116-NS-19-9 antibody
does not recognized sLea by immunohistochemistry but instead
other structures unknown at present, not located on the cell mem-
brane. Interestingly, a similar reactivity pattern was also found in a
colon adenocarcinoma. Apparently, normal colon mucosa cells do
not synthesize such unknown molecules, which become detectable
during neoplastic transformation being produced by the tumor
itself or by the surrounding tissue. Since histochemical reactiv-
ity with such antibody is sometimes assumed as a detection of
CA19.9 antigen in cancer tissues (Portela et al., 2011), such data
should be cautiously re-evaluated. This is particularly relevant in
colon adenocarcinomas, since we recently found that their glyco-
sylation machinery is unable to sustain relevant synthesis of sLea
(Mare et al., 2013), opening a question about the origin of the
CA19.9 antigen circulating in colon cancer patients. Taken together,
our recent and present ﬁndings indicate that neither the value of
serum CA19.9 nor the immunohistochemical detection of CA19.9
by 1116-NS-19-9 antibody in cancer sections predict the actual
expression of the antigen by colon cancer cells, as it has been
assumed so far. On the other side, they suggest that the assessment
of the actual sLea status of a colon cancer may  be very important for
the prognosis, since we proved that expression of the true antigen
promotes angiogenesis and, in turn, tumor growth.
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